Gilead Sciences Inc (GILD)
NASDAQ · Healthcare · Drug Manufacturers - General
Gilead Sciences Inc is a Healthcare company with a market capitalization of $158.77B, a trailing P/E ratio of 17.4, and a dividend yield of 2.58%.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 7, 2026 | $2.03 | $1.91 | +6.3% |
| Q4 2025 | February 10, 2026 | $1.86 | $1.81 | +2.8% |
| Q3 2025 | October 30, 2025 | $2.43 | $1.69 | +43.8% |
| Q2 2025 | August 7, 2025 | $2.01 | $1.96 | +2.5% |
| Q1 2025 | April 24, 2025 | $1.81 | $1.78 | +1.7% |
| Q4 2024 | February 11, 2025 | $1.90 | $1.70 | +11.7% |
Other Drug Manufacturers - General Stocks
Frequently Asked Questions
What is Gilead Sciences Inc's market cap?
As of June 29, 2026, Gilead Sciences Inc (GILD) has a market capitalization of $158.77B.
What is Gilead Sciences Inc's P/E ratio?
Gilead Sciences Inc trades at a trailing price-to-earnings (P/E) ratio of 17.4. Its forward P/E is 15.2.
Does Gilead Sciences Inc pay a dividend?
Yes — Gilead Sciences Inc pays a dividend yielding 2.58%, an annual payout of $3.19 per share.
What sector is GILD in?
Gilead Sciences Inc is in the Healthcare sector, specifically the Drug Manufacturers - General industry.
What was Gilead Sciences Inc's revenue?
In its latest reported fiscal year (ending December 31, 2025), Gilead Sciences Inc reported revenue of $29.44B and net income of $8.51B.
Ask your own questions about GILD
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.